Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/174286
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMallandrich Miret, Mireia-
dc.contributor.authorCalpena Campmany, Ana Cristina-
dc.contributor.authorClares Naveros, Beatriz-
dc.contributor.authorParra Coca, Alexander-
dc.contributor.authorGarcía López, María Luisa-
dc.contributor.authorSoriano-Ruiz, José L.-
dc.contributor.authorFrancisco Fernández-Campos-
dc.date.accessioned2021-02-25T07:02:53Z-
dc.date.available2022-02-15T06:10:19Z-
dc.date.issued2021-02-15-
dc.identifier.issn1743-5889-
dc.identifier.urihttp://hdl.handle.net/2445/174286-
dc.description.abstractAim: The development and optimization of Ketorolac tromethamine-loaded polylactic-co-glycolic acid nanoparticles (KT-NPs) for the treatment of inflammatory processes of the eye. Materials & methods: KT-NPs were developed by factorial design and characterized by assessing their physicochemical properties. Biopharmaceutical behavior studies, ocular tolerance, anti-inflammatory efficacy and bioavailability tests were performed on pigs. Results: Optimized KT-NPs of 112 nm, narrow distribution with encapsulation efficiency near 100% were obtained. KT release followed the Weibull model and there was significantly greater retention in the cornea and sclera than in the commercial reference. KT-NPs showed no signs of ocular irritancy and similar anti-inflammatory efficacy to the commercial reference. Conclusion: KT-NPs were a suitable alternative for the treatment of inflammatory disorders of the anterior and posterior segments of the eye as an alternative to conventional topical formulations.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherFuture Medicine-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.2217/nnm-2020-0403-
dc.relation.ispartofNanomedicine, 2021, vol. 13, num. 3-
dc.relation.urihttps://doi.org/10.2217/nnm-2020-0403-
dc.rights(c) Future Medicine, 2021-
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)-
dc.subject.classificationOftàlmia-
dc.subject.classificationAgents antiinflamatoris-
dc.subject.classificationNanopartícules-
dc.subject.classificationAdministració de medicaments-
dc.subject.otherOphthalmia-
dc.subject.otherAntiinflammatory agents-
dc.subject.otherNanoparticles-
dc.subject.otherAdministration of drugs-
dc.titleNano-engineering of ketorolac tromethamine platforms for ocular treatment of inflammatory disorders-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec707250-
dc.date.updated2021-02-25T07:02:53Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
707250.pdf651.8 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.